Alopecia areata is a common autoimmune hair loss disorder. It affects people of all age groups and ethnicities.

The disease is unpredictable and can initially present as small, well-defined patches of hair loss on the scalp, to complete loss of scalp and body hair.

While the causes of alopecia areata are not fully understood, it is believed to be the result of complex immune signals that change the hair growth cycle, resulting in hair loss

The JAK inhibitor is a newer type of medication that’s changing patients’ lives. It’s helping some patients with alopecia areata regrow their hair. Janus kinase (JAK) inhibitors work inside the body and it is thought to disrupt an immune signaling pathway involved in alopecia areata.

Before you use these medicines, tell your doctor if you:

• Are being treated for an infection, have an infection that won’t go away or keeps coming back, or think you have symptoms of an infection.
• Have TB or have been in close contact with someone with TB.
• Have had shingles (herpes zoster).
• Have had hepatitis B or C, cancer, or blood clots in the veins of your legs or lungs.
• Have had a heart attack, other heart problems or stroke.
• Have other medical conditions, including kidney or liver problems, low blood cell counts, diabetes, lung disease, HIV, or a weak immune system.
• Have any stomach-area pain or have been diagnosed with inflammation in the large intestine (diverticulitis) or ulcers in your stomach or intestines.
• Have recently received or plan to receive a vaccine. People taking JAKS should not receive live vaccines.
• Are pregnant or plan to become pregnant. 
• Are breastfeeding or plan to breastfeed. 
• Are taking other medicines, including prescription and over-the-counter medicines, vitamins, and herbal supplements. It is especially important to tell your doctor, if you take:
  • a medicine called probenecid
  • medicines that affect your immune system, such biologic medications, other JAK inhibitors, or strong immunosuppressants (such as azathioprine or cyclosporine) since these may increase your risk of infection.

Ordering prescription drugs such as Xeljanz and Olumiant online is a simple 3-step process:

1. Answer basic health questions as part of an online doctor visit.
2. A partner doctor reviews your information, and if appropriate, approves your prescription.
3. Your medication will be shipped to your door.

Rxfor.me offers the following prescription medications: Xeljanz, Olumiant/Unamity, and Rinvoq.

Yes, a doctor will review your responses to the Alopecia questionnaire and, based on the information you provide and any follow-up questions, will determine if you are an ideal candidate for the treatments we offer. When appropriate, the doctor will provide you with a prescription, and advise about a suitable treatment plan and dosage.

Generally, the intake requires details about your medical history, other medicines you’re taking, and general health information.

While Xeljanz can be effective for these conditions, it is essential to be aware of potential side effects. Common side effects of Xeljanz may include:

• Upper respiratory tract infections
• Headaches
• High blood pressure
• Increased liver enzyme levels
• Nausea
• Diarrhea
• Elevated cholesterol levels

Serious side effects are less common but can include:

• Increased risk of serious infections, including tuberculosis
• Blood clots
• Gastrointestinal perforations
• Elevated liver enzymes
• Changes in blood cell counts
• Risk of certain cancers, particularly lymphoma

The safety and side effects of Xeljanz can vary depending on the specific condition being treated and individual patient factors. It is crucial for individuals considering or using Xeljanz to have a thorough discussion with their healthcare provider. Patients should be closely monitored for potential side effects, and the benefits and risks of the medication should be carefully weighed.

Warnings Before Taking Xeljanz:

1. Infections: Xeljanz may increase the risk of serious infections, including tuberculosis (TB), bacterial, fungal, and viral infections. Prior to starting Xeljanz, patients should be screened for TB, and ongoing monitoring for signs of infection is essential during treatment.

2. Malignancies: There have been reports of an increased risk of certain cancers, including lymphoma, with the use of Xeljanz. Patients with a history of cancer or those at higher risk may require careful evaluation of the benefits and risks of treatment.

3. Blood Clots: Xeljanz has been associated with an increased risk of blood clots in the lungs and deep veins, which can be life-threatening. Patients with a history of blood clots or risk factors for clotting disorders should discuss this with their healthcare provider.

4. Gastrointestinal Perforations: Rare cases of gastrointestinal perforations have been reported with Xeljanz. Patients with a history of diverticulitis or other gastrointestinal conditions should exercise caution and report any abdominal symptoms promptly.

5. Liver Function: Xeljanz can lead to elevated liver enzyme levels. Liver function should be monitored regularly, and patients with liver disease should be closely observed.

6. Blood Cell Counts: Xeljanz can affect blood cell counts, including lowering the number of white blood cells, which are essential for fighting infections. Regular blood tests may be necessary during treatment.

7. Vaccinations: Live vaccines should not be administered while taking Xeljanz due to the risk of infection. Consult with your healthcare provider regarding recommended vaccinations before starting treatment.

8. Pregnancy and Breastfeeding: Xeljanz may have potential risks during pregnancy, and it can pass into breast milk. Discuss pregnancy planning and breastfeeding considerations with your healthcare provider.

9. Interactions: Inform your healthcare provider of all medications, supplements, and herbal products you are taking, as Xeljanz may interact with other drugs.

These warnings and precautions highlight the importance of close medical supervision and informed decision-making when considering Xeljanz as a treatment option. Before starting Xeljanz or any medication, individuals should have a thorough discussion with their healthcare provider to assess the potential benefits and risks based on their specific medical history and condition. Regular monitoring and open communication with a healthcare professional are key to safe and effective use.

1. Yes, Janus kinase (JAK) inhibitors have been investigated in clinical trials for the treatment of alopecia areata, an autoimmune hair loss condition. JAK inhibitors are a class of medications that target the immune system’s inflammatory response, which plays a role in alopecia areata’s development.

   Several JAK inhibitors have been studied in clinical trials for alopecia areata, including:

   1. Tofacitinib (Xeljanz): Tofacitinib is a JAK inhibitor that has shown promise in clinical trials for alopecia areata. Research has indicated that it can stimulate hair regrowth in some individuals with this condition.

   2. Ruxolitinib (Jakafi): Ruxolitinib is another JAK inhibitor that has been studied in the context of alopecia areata. Clinical trials have explored its efficacy in promoting hair regrowth.

   3. Baricitinib (Olumiant): Baricitinib, like the other JAK inhibitors, has been evaluated in clinical trials for alopecia areata, particularly in individuals with moderate to severe forms of the condition.

   The results of these clinical trials have shown varying degrees of success, with some patients experiencing significant hair regrowth while others may not respond as effectively. The use of JAK inhibitors for alopecia areata is still an area of ongoing research and development, and the long-term safety and efficacy of these medications for this condition continue to be studied.

   If you or someone you know is interested in exploring JAK inhibitors or other treatments for alopecia areata, it’s essential to consult with a dermatologist or healthcare provider who specializes in hair disorders. They can provide guidance on the most appropriate treatment options based on individual circumstances and the latest research findings.